CLOVER HEALTH INVESTMENTS, CORP. /DE 8-K/A

What Happened
Clover Health Investments, Corp. announced on March 6, 2026 that it has published a supplemental shareholder Q&A under Regulation FD to accompany its fourth quarter 2025 earnings announcement. The company furnished the written responses to selected frequently asked questions as Exhibit 99.1 to the Form 8‑K and posted the Q&A on its investor relations website. The Form 8‑K was signed by CFO Peter Kuipers.

Key Details

• The disclosure is a Regulation FD supplemental Q&A related to the company’s Q4 2025 earnings announcement.
• The Q&A was furnished as Exhibit 99.1 to the Form 8‑K filed on March 6, 2026.
• The company made the responses available on its investor relations section to engage with shareholders.
• The Form 8‑K was signed by Peter Kuipers, Chief Financial Officer (Principal Financial and Accounting Officer).

Why It Matters
This filing provides investors with additional, company‑authorized explanations following Clover Health’s Q4 2025 earnings release, which can clarify management’s views and address common investor questions. Because the information was furnished under Regulation FD and posted publicly, it is an official source for understanding management commentary tied to the quarterly results. Investors should review the Exhibit 99.1 Q&A on Clover’s investor site for details that may affect their view of the company’s recent performance and guidance.